News in the Life Sciences Industry

INCHEON, South Korea, Aug. 4, 2020 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) today held an online ceremony to announce the launch of its proprietary cell line technology, S-CHOice.

- Export of test kit to entire Europe and numerous countries that recognize CE-IVD gains impetus

SONGDO, South Korea, July 20, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) announced a plan to expand its Drug Product (DP) capability in line with increasing market demand and to ensure flexible production capabilities for new and existing clients.

SINGAPORE, July 20, 2020 /PRNewswire/ -- Docquity, Southeast Asia's largest professional network of doctors, has partnered with Swiss research-based healthcare company Novartis to deliver bite-sized, continual learning, and education support to doctors across seven countries in Asia. Novartis... Read more ››

SONGDO, South Korea, July 15, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and ImmuneOncia Therapeutics held a signing ceremony today for a contract to develop and manufacture five candidate molecules, expanding upon the two companies' existing CDO partnership first established in 2018.

SEONGNAM, South Korea and BASEL, Switzerland, July 14, 2020 /PRNewswire/ -- Bridge Biotherapeutics Inc.(KOSDAQ: 288330), a clinical stage biotech company headquartered in Seongnam, Republic of Korea and BaseLaunch, the Basel Area-based biotech venture accelerator and incubator, today announces... Read more ››

SONGDO, South Korea, July 11, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has further expanded its partnership with STCube through an additional development and manufacturing service agreement of STM418, an anti-PD1 immuno-oncology candidate.